[라포르시안] Dong-A Socio Holdings announced on the 4th that its consolidated sales in the first quarter of this year were 223.3 billion won, an increase of 16.2% compared to the same period of the previous year thanks to the even sales growth of its major subsidiaries.
According to the announcement, operating profit in the first quarter was 5.4 billion won, down about 2 billion won compared to the same period of the previous year, and net profit also turned into a loss by about 6.8 billion won to 800 million won compared to the same period last year.
In response, Dong-A Socio Holdings explained that this was due to the preemptive execution of marketing (sales and administrative expenses) expenses in the first quarter to expand sales.
Dong-A Pharmaceutical, a company specializing in over-the-counter drugs, recorded sales of KRW 114.8 billion, a 20.6% increase compared to the same period last year, thanks to sales growth in all divisions including Bacchus, over-the-counter (OTC) and health functional foods.
On the other hand, operating profit decreased by 13.7% to KRW 5.1 billion due to the concentrated execution of SG&A expenses, and net income also decreased by 9.2% to KRW 3.7 billion.
Yongma Logis, a logistics company, posted sales of KRW 77.1 billion, an increase of 9.7% compared to the same period last year, thanks to the expansion of the logistics market and the attraction of new shippers.
The company said that it turned to the red, recording an operating loss of 1.2 billion won and a net loss of 1.3 billion won due to an increase in overall logistics costs and preemptive investment for annual sales growth.
Biopharmaceutical company ESTGENBIO recorded sales of KRW 3.9 billion, a decrease of 17.9% compared to the same period last year, with operating profit of KRW 3.4 billion and net profit of KRW 3.6 billion.
Dong-A Socio Holdings said that the operating profit decreased compared to the same period last year, and the cost ratio is improving due to overall process improvement.
